Tanigawara, Y <br/><br/>
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.  [electronic resource] 

 -  Clinical pharmacology and therapeutics  Nov 1999 
 - 528-34 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0009-9236 
<br/><br/><label>Standard No.: </label>10.1016/S0009-9236(99)70017-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amoxicillin--therapeutic use<br/>Antacids--therapeutic use<br/>Anti-Bacterial Agents--therapeutic use<br/>Anti-Ulcer Agents--pharmacology<br/>Aryl Hydrocarbon Hydroxylases<br/>Bismuth--therapeutic use<br/>Clarithromycin--therapeutic use<br/>Cytochrome P-450 CYP2C19<br/>Cytochrome P-450 Enzyme Inhibitors<br/>Cytochrome P-450 Enzyme System--genetics<br/>Drug Therapy, Combination<br/>Enzyme Inhibitors--pharmacology<br/>Gastritis--drug therapy<br/>Genotype<br/>Helicobacter Infections--drug therapy<br/>Helicobacter pylori--drug effects<br/>Histamine H2 Antagonists--therapeutic use<br/>Humans<br/>Metronidazole--therapeutic use<br/>Mixed Function Oxygenases--antagonists & inhibitors<br/>Omeprazole--pharmacology<br/>Penicillins--therapeutic use<br/>Peptic Ulcer--drug therapy<br/>Polymerase Chain Reaction<br/>Polymorphism, Restriction Fragment Length<br/>Protein Synthesis Inhibitors--therapeutic use<br/>Treatment Outcome